Antibody Titer, Blood and Serum
Use
This test is used for monitoring antibody levels during pregnancy to help assess the risk of hemolytic disease of the newborn. It evaluates the presence of maternal IgG alloantibodies to red blood cell antigens, which can cross the placenta and cause hemolysis of antigen-positive fetal red blood cells, potentially leading to fetal anemia and hyperbilirubinemia. The test plays a critical role in assessing the risk and guiding management strategies for affected pregnancies.
Special Instructions
Testing is performed only on individuals assigned female at birth and who are pregnant or of child-bearing age to determine risk for hemolytic disease of the newborn. If antibodies are detected that are not clinically significant or are too weakly reactive, this test will be canceled in favor of an antibody identification test, ordered and performed at an additional charge. Specimen must arrive within 72 hours of collection.
Limitations
This test is not suitable for monitoring the efficacy of Rh-immune globulin administration and may not be performed if ordered outside the specified patient population criteria (pregnant women or those of child-bearing age). Recent administration of Rh-immune globulin may cause anti-D to be identified falsely as an alloantibody. There is no rejection criteria for specimens received, implying a broad acceptance spectrum as long as handling guidelines are followed.
FDA ApprovedNew York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 50962-0
- 888-8
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
3 mL
Minimum Volume
6 mL EDTA
Container
6-mL Pink top (EDTA)
Collection Instructions
Centrifuge and aliquot plasma into plastic vial. Label as EDTA plasma, send both tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |
| Refrigerated | 4 days |